Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 3,754 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phase duration Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

NCT03115112
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Sitagliptin, Placebo for sitagliptin, Placebo for bexagliflozin
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Lincoln, California • Long Beach, California • San Dimas, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Phase 1 Interventional

Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

NCT01433965
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Lenalidomide
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Phase 1 Interventional

Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects

NCT01110031
View directory record Official record
Conditions
Leukaemia, Lymphocytic, Chronic
Interventions
Ofatumumab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Not applicable Interventional

Intraoperative Radiation Therapy in Early Stage Breast Cancer

NCT02266602
View directory record Official record
Conditions
Breast Cancer
Interventions
Intraoperative Radiation Therapy
Radiation
Lead sponsor
Benaroya Research Institute
Other
Eligibility
45 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers

NCT00782600
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
suspension IR, CR 1, CR 2, CR 3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 9, 2009 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Phase 2 Interventional Results available

Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection

NCT01927744
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Docetaxel, Erlotinib, Placebo, Questionnaires, Phone Call, Chemotherapy
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 31, 2026, 10:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)

NCT05377905
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Skin Cancers - Squamous Cell Carcinoma
Interventions
Microneedle Array Doxorubicin (MNA-D)
Drug
Lead sponsor
Falo, Louis, MD
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 31, 2026, 10:50 AM EDT
Terminated Phase 2 Interventional Results available

Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy

NCT00766636
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Radiation Therapy, Erlotinib, Surgery
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 31, 2026, 10:50 AM EDT
Not listed Phase 2 Interventional

Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass

NCT02771509
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
ANG-3777, Placebo
Drug
Lead sponsor
Angion Biomedica Corp
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
23
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 31, 2026, 10:50 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

FACE Phase II (a Stage II Trial)

NCT07130669
View directory record Official record
Conditions
MCI, Subjective Cognitive Decline (SCD), Mild Behavioral Impairment
Interventions
Cognitive Remediation, Cognitive Remediation II
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
60 Years to 89 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 31, 2026, 10:50 AM EDT
Terminated Phase 1 Interventional

Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

NCT00775502
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BIW-8962
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Tampa, Florida • Chicago, Illinois • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Menstrual-phase-dependent Differences in Response to Sleep Loss

NCT05381532
View directory record Official record
Conditions
Sleep Deprivation
Interventions
Controlled sleep
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 31, 2026, 10:50 AM EDT
Terminated Phase 2 Interventional Results available

Antihistamines in Eosinophilic Esophagitis

NCT04248712
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Famotidine, Loratadine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 31, 2026, 10:50 AM EDT
Recruiting Not applicable Interventional

Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients

NCT05016219
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Circadian-Effective Light, Rhythmic Light, Placebo Light, Placebo Rhythmic Light
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Menands, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Not applicable Interventional

The Lifestyle Education About Nutrition for Diabetes (Legend) Study

NCT05237128
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Very low-carbohydrate diet, Moderate-carbohydrate plate-method diet
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
San Francisco, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 10:50 AM EDT
Terminated Phase 1 Interventional Results available

Oral Rehydration Therapy in Burn Patients

NCT02124265
View directory record Official record
Conditions
Burn Any Degree Involving 20-29 Percent of Body Surface, Burn Any Degree Involving 30-39 Percent of Body Surface, Burn Any Degree Involving 40-49 Percent of Body Surface, Burn Any Degree Involving 50-59 Percent of Body Surface, Burn Any Degree Involving 60-65 Percent of Body Surface, Fluid Resuscitation
Interventions
CeraLyte 90
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 31, 2026, 10:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT02810951
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica, Recessive
Interventions
FCX-007
Genetic
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
7 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Phase 1 Interventional

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

NCT03089645
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
MEDI5083 monotherapy, MEID5083 with Durvalumab or Tremelimumab, Medi5083 with Durvalumab and Docetaxel
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 101 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Hackensack, New Jersey • Providence, Rhode Island • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity

NCT06638671
View directory record Official record
Conditions
Exercise Capacity, Metformin
Interventions
Metformin Hydrochloride, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 30 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Phase 1 Interventional

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

NCT04641871
View directory record Official record
Conditions
Metastatic Cancer, Solid Tumor
Interventions
Sym021, Sym022, Sym023, Irinotecan Hydrochloride
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 31, 2026, 10:50 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Groceries for Residents of Southeastern USA to Stop Hypertension

NCT06891911
View directory record Official record
Conditions
Hypertension, Elevated Blood Pressure, Cardiovascular Diseases, Dietary Intervention
Interventions
Dietitian-Assisted DASH groceries, Self-directed shopping
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia

NCT02500836
View directory record Official record
Conditions
Any Ear Nose or Throat Conditions, With Identified Need for a Diagnostic Procedure or Surgery on or Through the Mucous Membranes of the Nasal Cavities
Interventions
Cocaine HCl 4% Topical Solution, Cocaine HCl 10% Topical Solution, Placebo Topical Solution
Drug
Lead sponsor
Lannett Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 31, 2026, 10:50 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Pilot Study of Teacher-Child Interaction Training - Universal in Head Start

NCT04075071
View directory record Official record
Conditions
Child Behavior, Child Development, Child Behavior Problem
Interventions
Teacher-Child Interaction Training - Universal
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
3 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 31, 2026, 10:50 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Training Strategies to Maintain Performance

NCT07128511
View directory record Official record
Conditions
Shortness of Breath, Shortness of Breath/Dyspnea, Respiratory Distress
Interventions
Multiple Inhalation Breathing Pattern, Tactical Breathing Technique
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 31, 2026, 10:50 AM EDT